Aldevron has announced the immediate availability of Nanoplasmids and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing. Through a license agreement with Nature Technology Corporation (NTC), Aldevron can now provide its clients the option of using NTC’s plasmid technology to provide a more efficient system for manufacturing viral vectors used in gene and cell therapy. Gene and cell therapy companies interested in using NTC’s technology can now go directly to Aldevron for their manufacturing needs without first obtaining a license from NTC. For applications where the NTC plasmid is not the active pharmaceutical ingredient or in the final product clients do not need to pay any royalties or license fees beyond the purchase price of the product.
 
“Gene and cell therapy researchers continue to make incredible discoveries that will improve lives for millions of people,” said Michael Chambers, chief executive officer, Aldevron. “Aldevron is committed to providing the best manufacturing technologies to support their breakthrough treatments. Our partnership with NTC enables us to provide plasmid technology that significantly improves the manufacturing process and reduces regulatory risk, resulting in reduced costs and faster time to patients.”
 
The fields of gene and cell therapy are surging with the approvals of Kymriah and Yescarta CAR-T treatments for cancer and Luxturna for the treatment of Leber congenital amaurosis, a rare genetic ocular disease. With nearly 3,000 clinical trials underway, improvements in manufacturing are required to provide the capacity to accommodate the growth in research and anticipated commercial products. The NTC technology, combined with Aldevron’s unequaled scale and throughput, assure clients will have the products they need.
 
“Our Nanoplasmid and RNA-OUT technology has been under development for 12 years and can provide demonstrable advantages for viral vector manufacturing,” said Clague Hodgson, chief executive officer, NTC. “We are pleased to collaborate with Aldevron to make this technology immediately available to its clients so they can avoid the delay and expense associated with the licensing process thereby reducing the barriers to delivering transformative treatments to patients.”